ONVO Organovo Holdings
- 0.960
- +0.050+5.49%
- 0.697
- -0.263-27.41%
Organovo Holdings News
Express News | Reported Earlier, Organovo Prices $5.25M Public Offering Of 6,562,500 Common Shares And Common Warrants At A Combined Price Of $0.80
Organovo Holdings, Inc. Announces Pricing Of $5.25M Public Offering Of 6,562,500 Shares Of Common Stock And Common Warrants At A Combined Price Of $0.80
Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise
Organovo Holdings' Offering of 6.6 Million Shares and Warrants Prices at 80 Cents a Share and Warrant
Organovo Holdings' Offering of 6.6 Million Shares and Warrants Prices at 80 Cents a Share and Warrant
Organovo Holdings Announces Pricing of $5.25M Public Offering
Organovo Holdings Announces Pricing of $5.25M Public Offering
Press Release: Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Holdings Shares Corporate Update Presentation
INVO, EZGO and WISA Among Pre-market Losers
Significant reduction in liver fat! Organovo Holdings (ONVO.US) announces positive trial results for MASH therapy
Organovo Holdings (ONVO.US) announced the positive results of its phase 2 trial of the drug FXR314 for the treatment of patients with metabolic function-related steatohepatitis (MASH).
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersDynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 23.4
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
Why Organovo Stock Is Up Today
Organovo Holdings, Inc. (NASDAQ:ONVO) shares are trading higher Monday after the company announced Phase 2 results for FXR314. The Details:Organovo released the complete details of its 16-week, random
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also
Express News | Organovo Shares Are Trading Higher After the Company Announced Phase 2 Results for FXR314. Study Results Demonstrated Statistically Significant Reduction in Liver Fat Content From Baseline in Patients Receiving FXR314 Compared to Placebo
Market-Moving News for April 15th
GS: 4.5% | Goldman Sachs shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.LGVN: 82% | Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating
Express News | Shares of Organovo Holdings up 19.6% Premarket as Fatty Liver Disease Drug Meets Main Goal in Mid-Stage Study
Express News | Organovo Announces Phase 2 Results For FXR314; Says 'Study Subjects Receiving FXR314 Achieved Statistically Significant Reduction in Liver Fat Content From Baseline'
Express News | Organovo Holdings Inc: Treatment-Emergent Adverse Events Were Mostly Mild to Moderate in Severity
Express News | Organovo Holdings:Study Showed Statistically Significant Reduction in Liver Fat Content From Baseline in Patients Receiving Fxr314 Compared to Placebo
Express News | Organovo Holdings Inc - Fxr314 Was Also Found to Be Safe and Well Tolerated
Analysis
Price Target
No Data
